Teriparatide therapy in joint replacement surgery: mitigating complications and improving patient outcomes in osteoarthritis
DOI:
https://doi.org/10.18203/issn.2455-4510.IntJResOrthop20234049Keywords:
Osteoarthritis, Teriparatide, Joint replacement surgery, Post-surgical complicationsAbstract
Background: Teriparatide, a synthetic form of parathyroid hormone, has gained significant recognition as an effective treatment for osteoporosis. Its ability to stimulate bone formation and improve bone mineral density has made it a valuable therapeutic option in managing this prevalent skeletal disorder. However, its safety and potential benefits in preventing bone mineral density (BMD) loss after joint replacement surgery and post-surgical complications have yet to be extensively investigated.
Methods: This retrospective study included 32 patients who received teriparatide following joint replacement surgery for osteoarthritis. The analysis focused on assessing teriparatide’s effectiveness in any reductions in post-surgical complications and adverse events, if any.
Results: No teriparatide-related adverse events and post-surgical complications were reported during the follow-ups and the entire study duration.
Conclusions: Teriparatide demonstrated effectiveness in joint replacement patients. Further research is needed to explore long-term benefits and effects on implant longevity.
References
Chen D, Shen J, Zhao W, Wang T, Han L, Hamilton JL, et al. Osteoarthritis: toward a comprehensive understanding of the pathological mechanism. Bone Res. 2017;5(1):16044.
Abramoff B, Caldera FE. Osteoarthritis. Med Clin North Am. 2020;104(2):293-311.
Grässel S, Muschter D. Recent advances in the treatment of osteoarthritis. F1000Res. 2020;9:325.
Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol. 2011;23(5):471-8.
Singh A, Das S, Chopra A, Danda D, Paul BJ, March L, et al. The burden of osteoarthritis in India and its states, 1990–2019: findings from the Global Burden of disease study 2019. Osteoarthritis Cartilage. 2022;30(8):1070-8.
Pal CP, Singh P, Chaturvedi S, Pruthi KK, Vij A. Epidemiology of knee osteoarthritis in India and related factors. Indian J Orthop. 2016;50(5):518-22.
Kumar A, Goel S, Gupta R, Gupta BM. Osteoarthritis research in India: A scientometric assessment of publications output during 2007–16. Int J Informat Disseminat Technol. 2017;7(3):157.
Lee DH, Kim SJ, Kim SA, Ju G. Past, present, and future of cartilage restoration: from localized defect to arthritis. Knee Surg Relat Res. 2022;34(1):1.
Colibazzi V, Coladonato A, Zanazzo M, Romanini E. Evidence-based rehabilitation after hip arthroplasty. HIP Int. 2020;30(2):20-9.
Nutt JL, Papanikolaou K, Kellett CF. Complications of total hip arthroplasty. Orthop Trauma. 2013;27(5):272-6.
Elsiwy Y, Jovanovic I, Doma K, Hazratwala K, Letson H. Risk factors associated with cardiac complication after total joint arthroplasty of the hip and knee: a systematic review. J Orthop Surg Res. 2019;14(1):15.
Heo SM, Harris I, Naylor J, Lewin AM. Complications to 6 months following total hip or knee arthroplasty: observations from an Australian clinical outcomes registry. BMC Musculoskelet Disord. 2020;21(1):602.
Dave D, Bhattacharjee SK, Shah DD, Mascerhans A, Dey PC, Arumugan S, et al. Osteoporosis in Indian Patients Undergoing Elective Arthroplasty and Spinal Procedures: An Observational Study. Cureus. 2022;14(7):e27275.
Sozen T, Ozisik L, Calik Basaran N. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4(1):46-56.
Tatangelo G, Watts J, Lim K, Connaughton C, Abimanyi-Ochom J, Borgström F, et al. The Cost of Osteoporosis, Osteopenia, and Associated Fractures in Australia in 2017. J Bone Mineral Res. 2019;34(4):616-25.
Bottai V, Dell'Osso G, Celli F, Bugelli G, Cazzella N, Cei E, et al. Total hip replacement in osteoarthritis: the role of bone metabolism and its complications. Clin Cases Miner Bone Metab. 2015;12(3):247-50.
LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporosis Int. 2022;33(10):2049-102.
Ji M, Yu Q. Primary osteoporosis in postmenopausal women. Chronic Dis Transl Med. 2015;1(1):9-13.
Bodenner D, Redman C, Riggs A. Teriparatide in the management of osteoporosis. Clin Interv Aging. 2007;2(4):499-507.
Orwoll E, Scheele W, Paul S, Adami S, Syversen U, Diez-Perez A, et al. The Effect of Teriparatide [Human Parathyroid Hormone (1-34)] Therapy on Bone Density in Men With Osteoporosis. J Bone Mineral Res. 2003;18(1):9-17.
Lyu H, Zhao SS, Yoshida K, Tedeschi SK, Xu C, Nigwekar SU, et al. Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use. J Clin Endocrinol Metab. 2019;104(11):5611-20.
Quattrocchi E, Kourlas H. Teriparatide: A review. Clin Ther. 2004;26(6):841-54.
Li G, Liu S, Xu H, Chen Y, Deng J, Xiong A, et al. Potential effects of Teriparatide (PTH (1–34)) on osteoarthritis: a systematic review. Arthritis Res Ther. 2023;25(1):3.
Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH. Teriparatide Reduces the Fracture Risk Associated with Increasing Number and Severity of Osteoporotic Fractures. J Clin Endocrinol Metab. 2005;90(3):1583-7.
Langdahl BL, Silverman S, Fujiwara S, Saag K, Napoli N, Soen S, et al. Real-world effectiveness of Teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies. Bone. 2018;116:58-66.
Minisola S, Cipriani C, Grotta G Della, Colangelo L, Occhiuto M, Biondi P, et al. Update on the safety and efficacy of Teriparatide in the treatment of osteoporosis. Ther Adv Musculoskelet Dis. 2019;11:1759720X1987799.
Hauser B, Alonso N, Riches PL. Review of Current Real-World Experience with Teriparatide as Treatment of Osteoporosis in Different Patient Groups. J Clin Med. 2021;10(7):1403.
Healy WL, Della Valle CJ, Iorio R, Berend KR, Cushner FD, Dalury DF, et al. Complications of total knee arthroplasty: standardized list and definitions of the Knee Society. Clin Orthop Relat Res. 2013;471:215-20.
Capone A, Congia S, Civinini R, Marongiu G. Periprosthetic fractures: epidemiology and current treatment. Clin Cases Miner Bone Metab. 2017;14(2):189-96.
Zushi Y, Takaoka K, Tamaoka J, Ueta M, Noguchi K, Kishimoto H. Treatment with Teriparatide for advanced bisphosphonate-related osteonecrosis of the jaw around dental implants: a case report. Int J Implant Dent. 2017;3(1):11.
Cavalli L, Brandi ML. Periprosthetic bone loss: diagnostic and therapeutic approaches. F1000Res. 2014;2:266.
Huang TW, Chuang PY, Lin SJ, Lee CY, Huang KC, Shih HN, et al. Teriparatide Improves Fracture Healing and Early Functional Recovery in Treatment of Osteoporotic Intertrochanteric Fractures. Medicine. 2016;95(19):e3626.
Kaneko T, Otani T, Kono N, Mochizuki Y, Mori T, Nango N, et al. Weekly Injection of Teriparatide for Bone Ingrowth after Cementless Total Knee Arthroplasty. J Orthop Surg. 2016;24(1):16-21.
Kobayashi N, Inaba Y, Uchiyama M, Ike H, Kubota S, Saito T. Teriparatide Versus Alendronate for the Preservation of Bone Mineral Density After Total Hip Arthroplasty – A randomized Controlled Trial. J Arthroplasty. 2016;31(1):333-8.
Lindsay R, Krege JH, Marin F, Jin L, Stepan JJ. Teriparatide for osteoporosis: importance of the full course. Osteoporosis Int. 2016;27(8):2395-410.
Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab. 2005;90(3):1583-7.
